Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pulmonx Corp before investing.

In this article, we go over a few key elements for understanding Pulmonx Corp’s stock price such as:

• Pulmonx Corp’s current stock price and volume
• Why Pulmonx Corp’s stock price changed recently
• Upgrades and downgrades for LUNG from analysts
• LUNG’s stock price momentum as measured by its relative strength

About Pulmonx Corp (LUNG)

Before we jump into Pulmonx Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Want to learn more about Pulmonx Corp’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pulmonx Corp.

Pulmonx Corp’s Stock Price as of Market Close

As of September 10, 2024, 4:00 PM, CST, Pulmonx Corp’s stock price was $7.75.

Pulmonx Corp is up 9% from its previous closing price of $7.11.

During the last market session, Pulmonx Corp’s stock traded between $6.95 and $7.31. Currently, there are 38.94 million shares of Pulmonx Corp stock available for purchase.

Unfortunately, Pulmonx Corp’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Pulmonx Corp Stock Price History

Pulmonx Corp’s (LUNG) price is currently up 5.87% so far this month.

During the month of September, Pulmonx Corp’s stock price has reached a high of $7.87 and a low of $6.31.

Over the last year, Pulmonx Corp has hit prices as high as $14.84 and as low as $5.46. Year to date, Pulmonx Corp’s stock is down 8.07%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pulmonx Corp Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 09, 2024, there were 5 analysts who downgraded Pulmonx Corp’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Pulmonx Corp’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pulmonx Corp’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pulmonx Corp’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pulmonx Corp (LUNG) by visiting AAII Stock Evaluator.

Relative Price Strength of Pulmonx Corp

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 09, 2024, Pulmonx Corp has a weighted four-quarter relative price strength of -8.86%, which translates to a Momentum Score of 34 and is considered to be Weak.

Want to learn more about how Pulmonx Corp is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pulmonx Corp Stock Price: Bottom Line

As of September 10, 2024, Pulmonx Corp’s stock price is $7.75, which is up 9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pulmonx Corp stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.